Rescue Treatment with Infliximab for a Bilateral, Severe, Sight Threatening
Frosted Branch Angiitis Associated with Concomitant Acute Onset of Presumed Dermatomyositis.
Ocul Immunol Inflamm 2022;
31:865-869. [PMID:
35394851 DOI:
10.1080/09273948.2022.2057333]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE
To report a severe bilateral frosted branch angiitis associated with acute onset of systemic dermatomyositis.
METHOD
History and clinical examination, laboratory evaluation, fundus' and skin's color pictures, fluorescein angiography (FA), optical coherence tomography (OCT).
RESULTS
A 32-year-old female was referred for a bilateral frosted branch angiitis and vitreitis, with skin rash, muscle pain, weakness, severe headache, compatible with dermatomyositis. After an initial improvement following an aggressive treatment by systemic steroids and mycophenolate mofetil, she was switched to intravenous infliximab (RemicadeTM, Janssen Biotech, Inc. USA) due to lack of efficacy. Nine months later, her visual acuity was improved up to 20/20 in OU, with both retinal vasculitis and vitreitis being solved.
CONCLUSION
Dermatomyositis is a severe multiorgan disease which might severely involve eye structures. Anti-TNF-Alpha agents, particularly Infliximab, might offer a rapid control and long-term remission.
Collapse